InMed Pharmaceuticals merges with Mentari Therapeutics

InMed Pharmaceuticals has entered into a merger agreement with Mentari Therapeutics, marking a strategic pivot for InMed from its cannabis-focused research to a neurology-centered business model. The merger, structured as an all-stock transaction, is bolstered by a sizeable $290 million private financing round aimed at sustaining operations until 2028. This maneuver seeks to establish a biotechnology entity with a strong footing in the migraine prevention landscape, capitalizing on Mentari’s biologics pipeline that targets new pathways beyond the customary CGRP focus.

Under the terms of the merger, which is expected to finalize by the second half of 2026, the new entity will operate as Mentari Therapeutics and maintain its listing on the Nasdaq. Pre-merger shareholders of InMed are anticipated to hold about 1.51% of the newly combined firm, which is estimated to possess a pro forma equity value of approximately $421.4 million inclusive of the recent financing. The capital infusion was led by a coalition of notable investors such as Janus Henderson Investors, Wellington Management, and Blackstone Multi-Asset Investing.

The merger reflects a calculated bid to harness the commercial and clinical potential of migraine therapies that move beyond CGRP monoclonal antibodies, addressing a significant gap where existing medications fail to significantly reduce migraine occurrences in approximately 40% to 50% of patients. Mentari’s lead candidates include an anti-PACAP monoclonal antibody and a bispecific antibody targeting both CGRP and PACAP pathways. These biologics are in various stages of development, with pivotal trials set to generate initial data between 2027 and 2028.

The shift signifies a broader trend within the biotechnology field, where private companies are increasingly leveraging mergers with publicly listed entities to gain access to the capital markets infrastructure necessary for expansive and costly drug development processes. This trend is evident as migraine research evolves to include multi-pathway treatments, in pursuit of improved outcomes for patients with refractory or partially responsive conditions. The attraction of targeting pituitary adenylate cyclase-activating polypeptide (PACAP) stems from its pivotal role in migraine pathophysiology and neurovascular signaling, drawing interest from leading pharmaceutical entities and biotechnology ventures alike.

As the merged company looks toward finalizing the transaction, the industry will be watching the development of Mentari’s pipeline closely. The successful integration and achievement of clinical milestones could set the stage for significant advances in migraine treatment paradigms, potentially redefining standards and enhancing therapeutic efficacy for millions affected by this complex neurological disorder.